D. Rosenberg

Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials

A. Gafter-Gvili, T. Avni, T. Diker-Cohen, 2020, Osteoporosis International.

Response to ethical challenges in stroke research

J. Grotta, P. Pepe, J. Rothrock, 1998 .

Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma

S. Trestman, Y. Herishanu, A. Kolomansky, 2018, Bone Marrow Transplantation.

Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-analysis.

A. Gafter-Gvili, T. Avni, T. Diker-Cohen, 2020, The Journal of clinical endocrinology and metabolism.

Predictors of an Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab: A Multicenter Study

V. Furer, Y. Braun-Moscovici, A. Balbir-Gurman, 2021 .

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.

E. Sprecher, D. Zeltser, V. Furer, 2022, JAMA.

Impact of a Multidisciplinary Nutritional Support Team (MNST) on Quality Improvement in Home Parenteral Nutrition (HPN)

M. Rothkopf, A. Tallman, F. Gagliardotto, 2022, medRxiv.

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

G. Shefer, V. Furer, I. Litinsky, 2021, Annals of the Rheumatic Diseases.

Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials

A. Gafter-Gvili, T. Avni, T. Diker-Cohen, 2021, Osteoporosis International.